Many people find stopping SSRIs difficult, experiencing prolonged and severe withdrawal symptoms, but researchers are still unsure why due to a lack of comprehensive studies and clear definitions, prompting calls for more research into the long-term effects of discontinuing antidepressants.
Experts warn that antidepressant withdrawal is a significant public health issue, especially for long-term users, with recent research indicating severe and lasting withdrawal symptoms that are often underestimated due to reliance on short-term, industry-funded studies. The UK government now recognizes this problem, which has been historically overlooked due to outdated guidelines and limited long-term data. A new review suggests current studies may underestimate withdrawal risks, emphasizing the need for better understanding and management of antidepressant discontinuation.
A study finds that longer use of antidepressants is linked to more severe, longer-lasting withdrawal symptoms, especially after more than two years of use, highlighting the need for careful discontinuation strategies and updated clinical guidelines.
A study published in The Lancet Psychiatry reveals that 15% of people discontinuing antidepressants experience withdrawal symptoms, with 3% facing severe symptoms. The research underscores the importance of healthcare support during the discontinuation process and aims to provide a balanced view on the prevalence and impact of these symptoms.
A review of 79 studies involving over 20,000 patients found that one in six people experience withdrawal symptoms when stopping antidepressants, fewer than previously thought. The study, published in The Lancet Psychiatry, suggests that while most people can stop antidepressants successfully, some may experience symptoms like dizziness, headache, nausea, and insomnia. The findings emphasize the importance of tapering off medication under medical supervision to minimize withdrawal effects.
A major study published in The Lancet Psychiatry reveals that only one in six patients experience withdrawal symptoms when stopping antidepressants, with severe symptoms affecting just 2-3% of users. This finding, based on data from 21,000 patients, suggests that discontinuation is less risky than previously thought, providing reassurance for those concerned about side effects. The study highlights the importance of a gradual tapering plan and professional support when discontinuing antidepressants.
A study published in Lancet Psychiatry found that 15% of people who stop taking antidepressants experience withdrawal symptoms, with 3% facing severe symptoms. Common symptoms include dizziness, headache, nausea, insomnia, and irritability. The study, which analyzed data from 79 studies involving 21,000 patients, noted that citalopram, sertraline, and fluoxetine had the lowest risk of symptoms, while imipramine, paroxetine, and desvenlafaxine had higher risks. The research emphasizes the need for proper counseling and support for patients discontinuing antidepressants.
A meta-analysis of 79 studies involving 21,002 adults found that about 15% of people who stop taking antidepressants experience withdrawal symptoms such as dizziness, headaches, and nausea. Severe symptoms were reported by 1 in 35 participants. The study highlights the importance of doctors and patients having informed discussions about discontinuing antidepressants safely.
Type 2 diabetes can often be prevented and treated with a lifestyle that includes regular moderate exercise and a mostly plant-based diet, with medication like metformin if necessary; gabapentin, a medication for chronic pain, can cause withdrawal symptoms such as tremors if stopped suddenly, and should be tapered slowly under medical supervision.
Benzodiazepines like Xanax and Valium, commonly prescribed for anxiety, have been linked to nervous system injury, negative life effects, memory issues, and cognitive decline. Many patients experience withdrawal symptoms and rebound anxiety when trying to stop using these drugs, with long-lasting symptoms such as low energy, difficulty focusing, memory loss, anxiety, insomnia, and more. The condition, known as benzodiazepine-induced neurological dysfunction (BIND), occurs in about one in five long-term users. The study highlights the need for further research and a change in how these drugs are prescribed.
More than a quarter of patients on antidepressants in England, about two million people, have been taking them for five years, despite limited evidence of the benefits of taking the drugs for that length of time. Withdrawal symptoms can make it hard for some to stop taking their medication. The investigation also uncovered evidence that a leading drug company attempted 27 years ago to conceal possible withdrawal effects that one drug could cause. There is some evidence to suggest that long-term antidepressant use may be linked to some health risks, such as heart problems and diabetes.
Coming off antidepressants can cause a range of withdrawal symptoms, including feeling as if there's an electric shock in your head, restlessness, trouble sleeping, and stomach problems. It's important to come off the medication slowly over a period of four weeks or longer to reduce the risk of suffering from these side-effects. Antidepressants are popular in the UK, with nearly half a million more adults in England starting to take them in 2022 compared to the previous year. If you decide to come off antidepressants, it's important to speak to your doctor and seek help and support from mental health charities like Mind.
Withdrawal symptoms from long-term use of antidepressants can last for months or even years, with about half of those who stop taking them experiencing severe symptoms. Misinformation about antidepressants has led to their overuse, with many falsely believing that withdrawal effects are mild and that the drugs are not addictive. Antidepressants do not work by correcting an underlying chemical imbalance, but rather by subtly changing normal mental states, producing emotional numbing among other effects. To safely stop antidepressants, guidelines recommend reducing doses in slow stages over months and sometimes years down to very low doses.